Perrigo attributes flat second quarter sales to slow start to cough/cold season.
This article was originally published in The Tan Sheet
PERRIGO SECOND QUARTER SALES FLAT AT $174.7 MIL. due to a slow start to the cough/cold season, the company said in a Feb. 7 release. "The second quarter was a difficult period for our company due to a very weak start to the cough and cold season this year, which negatively impacted sales of our largest product categories," Perrigo said. As a result, the firm explained, sales of cold remedies have been "below expectations.
You may also be interested in...
DJO Global will buy Trilliant Surgical to further its ongoing expansion into the US foot and ankle market.
Ying Huang was named CEO as his predecessor came under investigation in China and as partner Janssen was getting closer to seeking US FDA approval for its lead CAR-T therapy.
In addition to agreeing to emergency use of the Oxford University/Astra Zeneca and Sinovac vaccines, Brazil's medicines regulator has also published good manufacturing practices certificates for Pfizer and Janssen vaccine. It has questions about the Sputnik V authorization request.